Navigation Links
HeartWare to Report 2010 Fourth Quarter and Year-End Financial Results
Date:2/15/2011

FRAMINGHAM, Mass. and SYDNEY, Feb. 15, 2011 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) will release financial results for the fourth quarter and year ended December 31, 2010 prior to the open of the U.S. stock markets on Thursday, February 24, 2011.

A conference call with management is scheduled for 8:00 am U.S. Eastern Standard Time on Thursday, February 24, 2011 (being midnight Australian Eastern Daylight Time, between February 24 and February 25, 2011) to discuss the Company's financial results, highlights from the quarter and full year, and business outlook.  The call may be accessed by dialing 1-877-941-2322 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial + 1-480-629-9715.

A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Fourth Quarter Conference Call" under the section titled "Corporate Presentations" on the Home Page.  A replay of the conference call will be available through the above weblink immediately following completion of the call.

A copy of the news release announcing results and related information will be available on the Company's web site, www.heartware.com.

About HeartWare InternationalHeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.For further information:Christopher TaylorHeartWare International, Inc.Email: ctaylor@heartwareinc.comPhone: +1 508 739 0864
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International
2. HeartWare International, Inc. Temporary Suspension of Trading
3. HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
6. Par Pharmaceutical Reports Second Quarter 2008 Results
7. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
8. Pharmos Corporation Reports 2008 Second Quarter Results
9. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
10. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
11. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company ... Opinion Leader event to highlight new clinical data that ... at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the ... held in-person and via live webcast on Tuesday, February ... at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight ... for Cancer Research (OICR) are pleased to report that ... A financing, with Johnson & Johnson Innovation – JJDC, ... include venture groups HealthCap, TPG Biotechnology Partners, and Genesys ... ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life Sciences ... line of oncolytic vaccinia viruses for virotherapy research. ... part of Genelux,s proprietary, vaccinia virus-based technology platform ... to enter into a partnership with Genelux to ... vaccinia viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers ... CRP, adiponectin, uric acid, and/or other biomarkers or SNPs of interest) using one, ... Salimetrics’ SalivaLab , the relationship between insulin and other relevant biomarkers can be ...
Breaking Biology Technology:
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
(Date:2/2/2017)... 2, 2017  EyeLock LLC, a market leader of ... paper " What You Should Know About Biometrics in ... user authenticity is a growing concern. In traditional schemes, ... However, traditional authentication schemes such as username/password suffer from ... authentication offers an elegant solution to the problem of ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
Breaking Biology News(10 mins):